Inside Regeneron’s race to treat the latest outbreak
Last week, Regeneron Pharmaceuticals got a package of coronavirus, and scientists cleared their calendars.
The company is among a handful of drug and vaccine makers racing to help with 2019-nCoV, the pandemic virus that has killed more than 400 people since spreading from China. Over the last few days, Regeneron’s scientists have been sprinting through the drug development process, tapping the technology behind Eylea and Dupixent in hopes of coming up with an antibody that might halt 2019-nCoV.
The last time Regeneron broke the glass on its pandemic-response system, it had a human-ready treatment for Ebola in 10 months. But the latest outbreak’s uncertain future could render a treatment unnecessary by the time it’s ready for use. And even if the novel coronavirus persists, the unpredictability of drug development could leave Regeneron with nothing to show for its efforts.
Read more.
The company is among a handful of drug and vaccine makers racing to help with 2019-nCoV, the pandemic virus that has killed more than 400 people since spreading from China. Over the last few days, Regeneron’s scientists have been sprinting through the drug development process, tapping the technology behind Eylea and Dupixent in hopes of coming up with an antibody that might halt 2019-nCoV.
The last time Regeneron broke the glass on its pandemic-response system, it had a human-ready treatment for Ebola in 10 months. But the latest outbreak’s uncertain future could render a treatment unnecessary by the time it’s ready for use. And even if the novel coronavirus persists, the unpredictability of drug development could leave Regeneron with nothing to show for its efforts.
Read more.
.png)
No hay comentarios:
Publicar un comentario